1/2) Romosozumab^💉 Sclerostin* secteted by osteocytes binds to LRP 5/6 in osteoblast¹s → ↓Wnt signaling pathway² → ↓🦴 formation ^ inhibits * → → ↑² → β-catenin translocation into ¹ nucleus → ↑¹ survival/prolife https://t.co/dypCfVHpzx https://t.co/ylpgMYF
2/2) ^ROMO's *sclerostin inhibition also ➡️↓{RANKL dep osteoclast activity↑ & 🦴 resorp↑} https://t.co/dypCfVHpzx *https://t.co/3dv65cZjh3 ^ (1 yr) Tx³ be followed by ⁴anti-resorp Tx ∵ ⁴ ➡️ [🦴 mineral]→~↑↑ & Fx risk↓ even after ³ Fig.1 👉 https://t.c
2/2) ^'s *sclerostin inhibition also ➡️↓{RANKL dep osteoclast activity↑ & 🦴 resorp↑} https://t.co/dypCfVHpzx *https://t.co/3dv65cZjh3 ^ (1 yr) Tx³ should be followed by ⁴anti-resorp Tx ∵ ⁴ ➡️ [🦴 mineral]→~↑↑ & Fx risk↓ even after ³ Fig.1 https://t.
RT @sociedadSEEN: 🦴Clinical Utility of Romosozumab in the Management of Osteoporosis: Focus on Patient Selection and Perspectives 👉 #romos…
RT @sociedadSEEN: 🦴Clinical Utility of Romosozumab in the Management of Osteoporosis: Focus on Patient Selection and Perspectives 👉 #romos…
RT @sociedadSEEN: 🦴Clinical Utility of Romosozumab in the Management of Osteoporosis: Focus on Patient Selection and Perspectives 👉 #romos…
RT @sociedadSEEN: 🦴Clinical Utility of Romosozumab in the Management of Osteoporosis: Focus on Patient Selection and Perspectives 👉 #romos…
🦴Clinical Utility of Romosozumab in the Management of Osteoporosis: Focus on Patient Selection and Perspectives 👉 #romosozumab tiene una alta eficacia para el tratamiento de la #osteoporosis https://t.co/q9U4ubEkkb @oseoseen https://t.co/bBUgQlG0qI
Clinical Utility of Romosozumab in the Management of Osteoporosis: Focus on Patient Selection and Perspectives: No abstract https://t.co/beUwNdAfgM